Algernon Pharmaceuticals, Inc. (AGN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Pharmala Biotech Holdings, Inc.

Intellipharmaceutics International, Inc.

Telescope Innovations Corp.

NurExone Biologic, Inc.

BetterLife Pharma, Inc.

Tryp Therapeutics, Inc.

RepliCel Life Sciences, Inc.

Algernon Pharmaceuticals, Inc.

Appili Therapeutics, Inc.

EGF Theramed Health Corp.

Aequus Pharmaceuticals, Inc.

Why is Algernon Pharmaceuticals, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Algernon Pharmaceuticals, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Algernon Pharmaceuticals, Inc.

-42.14%

-0.60

91.55%

S&P/TSX 60

29.63%

1.43

14.72%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

13.05%

EBIT to Interest (avg)

-4.71

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.07

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.06%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.75

EV to EBIT

-0.80

EV to EBITDA

-0.85

EV to Capital Employed

0.73

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-91.20%

ROE (Latest)

-83.92%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

ROCE(HY)

Highest at 0%

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

OPERATING PROFIT(Q)

Highest at CAD 0.05 MM

NET PROFIT(Q)

Highest at CAD 0 MM

EPS(Q)

Highest at CAD 0

-10What is not working for the Company

INTEREST(9M)

At CAD 0.01 MM has Grown at inf%

NET PROFIT(9M)

At CAD -1.67 MM has Grown at -24.97%

ROCE(HY)

Lowest at -124.73%

DEBT-EQUITY RATIO (HY)

Highest at 42.06 %

PRE-TAX PROFIT(Q)

Lowest at CAD -0.7 MM

Here's what is working for Algernon Pharmaceuticals, Inc.

Operating Profit

Highest at CAD 0.05 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CAD MM)

Net Profit

Highest at CAD 0 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CAD MM)

Net Profit

At CAD 0 MM has Grown at 100%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CAD MM)

EPS

Highest at CAD 0

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CAD)

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Algernon Pharmaceuticals, Inc.

Interest

At CAD 0.01 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CAD MM)

Pre-Tax Profit

Lowest at CAD -0.7 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CAD MM)

Debt-Equity Ratio

Highest at 42.06 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio